Skip to main content
SpringerLink
Log in

Tyrosine Kinase Inhibitors in Preclinical Development

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Due to the limited efficacy of cytotoxic chemotherapy in the treatment of advanced malignancy and its excessive toxicity precluding its use in chemoprevention, new therapeutic and preventive strategies have been sought. One of the most interesting of these new approaches is the manipulation of signal transduction pathways. Among the approaches being considered to eventuate such a strategy is the inhibition of autophosphorylation, a critical first step in the signal transduction pathways of many cell surface receptor tyrosine kinases, as well as of non-receptor tyrosine kinases. This article is intended to review those tyrosine kinase inhibitors that are currently in preclinical development, for which there are data to support consideration for their use in chemoprevention or cancer treatment. We will focus upon those agents that have received attention in the past several years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Karin M, Hunter T: Transcriptional control by protein phosphorylation: signal transmission from the cell surface to the nucleus.Curr Biol 5: 747–757, 1995

    Google Scholar 

  2. Hill CS, Treisman R: Transcriptional regulation by extracellular signals: mechanisms and specificity.Cell 80: 199–211, 1995

    Google Scholar 

  3. Cooper GM: Oncogenes and growth factors.In: Oncogenes, Chap.11, pp.163–173, Boston: Jones and Bartlett Publishers, 1990

    Google Scholar 

  4. Kolibaba KS, Druker BJ: Protein tyrosine kinases and cancer.Biochem Biophys Acta 1333: F217–248, 1997

    Google Scholar 

  5. Porter AC, Vaillancourt RR: Tyrosiae kinase receptoractivated signal transduction pathways which lead to oncogenesis.Oncogene 17: 1343–1352, 1998

    Google Scholar 

  6. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity.Cell 61: 203–212, 1990

    Google Scholar 

  7. Schlessinger J, Ullrich A: Growth factor signaling by receptor tyrosine kinases.Neuron 9: 383–391, 1992

    Google Scholar 

  8. Fantl WJ, Johnson DE, Williams LT: Signalling by receptor tyrosine kinases.Annu Rev Biochem 62: 453–481, 1993

    Google Scholar 

  9. Heldin C-H: Dimerization of cell surface receptors in signal transduction.Cell 80: 213–223, 1995

    Google Scholar 

  10. Goldman R, Ben Levy R, Peles E, Yarden Y: Heterodimerization of the erbB-l and erba-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation.Biochemistry 29: 11024–11028, 1990.

    Google Scholar 

  11. Wada T, Qian X, Greene MI: Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function.Cell 61: 1339–1347, 1990

    Google Scholar 

  12. Groner B, Gouilleux F: Prolactin-mediated gene activation in mammary epithelial cells.Curr Opin Genet Dev 5: 587–594, 1995

    Google Scholar 

  13. Argetsinger LS, Carter-Su G: Mechanism of signaling by growth hormone receptor.Physiol Rev 76: 1089–1107, 1996

    Google Scholar 

  14. Carter-Su C, Schwartz J, Smit LS: Molecular roechanism of growth hormone action.Annu Rev Physiol 58: 187–207, 1996

    Google Scholar 

  15. Cambier JC: Signal transduction by T-and B-cell antigen receptors: converging structures and concepts.Curr Opin Immunol 4: 257–264, 1992

    Google Scholar 

  16. Keegan AD, Paul WE: Multichain immune recognition receptors: similarities in structure and signaling pathways.Immunot Today 13: 63–68, 1992

    Google Scholar 

  17. Weiss A, Littman DR: Signal transduction by lymphocyte antigen receptors.Cell 76: 263–274, 1994

    Google Scholar 

  18. Collette Y, Olive D: Non-receptor protein kinases as immune targets of viruses Immunol.Today 18: 393–400, 1997

    Google Scholar 

  19. Kishimoto T, Taga T, Akira S: Cytokine signal transduction.Cell 76: 253–262, 1994

    Google Scholar 

  20. Mui A, Miyajima A: Cytokine receptors and signal transduction.Prog Growth Factor Res 5: 15–35, 1994

    Google Scholar 

  21. Ihle JN: Cytokine receptor signalling.Nature 377: 591–594, 1995

    Google Scholar 

  22. Taniguchi T: Cytoldne signaling through nonreccptor protein tyrosine kinases.Science 268: 251–255, 1995

    Google Scholar 

  23. Wells J, de Vos A: Hematopoietic receptor complexes.Annu Rev Biochem 65: 609–634, 1996

    Google Scholar 

  24. Chan C-J, Geahlen RL: Protdn-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.J Net Prod (Lloydia) 55: 1529–1560, 1992

    Google Scholar 

  25. Smith JA, Francis SH, Corbin JD: Autophosphorylation: a salient feature of protein kinases.Mel Cell Biochem 127-128: 51–70, 1993

    Google Scholar 

  26. Bolen JB: Nonreceptortyrosine protein kinases.Oncogene 8: 2025–2031, 1993

    Google Scholar 

  27. Hunter T: Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling.Cell 80: 225–236, 1995

    Google Scholar 

  28. Tonks NK, Neel BG: From form to function: signaling by protein tyrosine phosphatases.Cell 87: 365–368, 1996

    Google Scholar 

  29. Matozaki T, Kasuga M: Roles of protein-tyrosine phosphatases in growth factor signalling.Cell Signal 8: 13–19, 1996

    Google Scholar 

  30. Pani G, Siminovitch KA: Protein tyrosine phosphatase roles in the regulation of lymphocyte signaling.Clin Immunol Immunopathol 84: 1–16, 1997

    Google Scholar 

  31. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J, Downward J, Mayes ELV, Whittle N, Waterfield MD, Seeberg PH: Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells.Nature 309: 418–425, 1984

    Google Scholar 

  32. Besmer P, Lader E, George PC, Bergold PJ, Qiu FH, Zuckerman EE, Hardy WD: A new acute transforming feline retrovirus with fms homology specifies a C-terminally truncated version of the c-fms protein that is different from SM-feline sarcoma virus v-fms protein.J Virol 60: 194–203, 1986

    Google Scholar 

  33. Smith DR, Vogt PK, Hayman MJ: The v-sea oncogene of avian erythroblastosis retrovirus S13: another member of the protein-tyrosine kinase gene family.Proc Natl Acad Sci USA 86: 5291–5295, 1989

    Google Scholar 

  34. van Daalen Wetters T, Hawkins SA, Roussel MF, Sherr CJ: Random mutagenesis of CSF-1 receptor (FMS) reveals multiple sites for activating mutations within the extracellular domain.EMBO J 11: 551–557, 1992

    Google Scholar 

  35. Bargmann CI, Weinberg RA: Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion.EMBO J 7: 2043–2052, 1988

    Google Scholar 

  36. Weiner DB, Liu J, Cohen JA, Williams WV, Greens MI: A point mutation in the neu oncogene mimics ligand induction of receptor aggregation.Nature 339: 230–231, 1989

    Google Scholar 

  37. Zong CS, Poon B, Chen J, Wang L-H: Molecular and biochemical bases for activation of the transforming potential of the proto-oncogene c-ros.J Virol 67: 6453–6462, 1993

    Google Scholar 

  38. Shu HK, Pelley RJ, Kung H-J: Tissue-specific transformation by epidermal growth factor receptor: a single point mutation within the ATP-binding pocket of the erbB product increases its intrinsic kinase activity and activates its sarcomagenic potential.Proc Natl Acad Sci USA 87: 9103–9107, 1990

    Google Scholar 

  39. McDonough SK, Larsen S, Brodey RS, Stock ND, Hardy Jr. WD: A transmissible feline fibrosarcoma of viral origin.Cancer Res 31: 953–956, 1971

    Google Scholar 

  40. Nowell PC, Hungerford DA: Chromosome studies on normal and leukemic human leukocytes.J Nat Cancer Inst 25: 85–109, 1960

    Google Scholar 

  41. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G: Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome22.Cell 36: 93–99, 1984

    Google Scholar 

  42. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G: Structural organization of the bcr gene and its role in the Ph′ translocation.Nature 315: 758–761, 1985

    Google Scholar 

  43. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D: The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene.Science 233: 212–214, 1986

    Google Scholar 

  44. Davis RL, Konopka JB, Witte ON: Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties.Mol Cell Biol 5: 204–213, 1985

    Google Scholar 

  45. Lugo T, Pendergast A-M, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.Science 247: 1079–1082, 1990

    Google Scholar 

  46. Hughes TP, Goldman JM: In: Hoffman R, Benz Jr. EJ, Shatil SJ, Furie B, Cohen HJ, Silberstein LE (Eds) Hematology: Basic Principles and Practice, 2nd ed., Churchill Livingstone, New York, pp.1142–1159, 1995

    Google Scholar 

  47. Shin DM, Ro JY, Hong WK, Hittelman WN: Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis.Cancer Res 54: 3153–3159, 1994

    Google Scholar 

  48. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K: Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung.Cancer Res 50: 7077–7080, 1990

    Google Scholar 

  49. Gorgoulis V, Aninos D, Mikou P, Kanavaros P, Karameris A, Joardanoglu J, Rasidakis A, Veslemes M, Ozanne B, Spandidos DA: Expression of EGF, TGF-alpha and EGFR in squamous cell lung carcinomas.Anticancer Res 12: 1183–1187, 1992

    Google Scholar 

  50. Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, Ali IU: Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors.Cancer Res 52: 4550–4553, 1992

    Google Scholar 

  51. Maxwell M, Naber SP, Wolfe HJ, Galanopoulos T, Hedley-Whyte ET, Black PM, Antoniades HN: Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance.J Clin Invest 86: 131–140, 1990

    Google Scholar 

  52. Hermanson M, Funa K, Hartman H, Claesson-Welsh L, Heldin C-H: Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops.Cancer Res 52: 3213–3229, 1992

    Google Scholar 

  53. Ross JS, Fletcher JA: The HER2/neu oncogene in breast cancer: prognostic factor, predictive factor and target for therapy.Stem Cells 16: 413–428, 1998

    Google Scholar 

  54. Talamonti MS, Roh MS, Curley SA, Gallick GE: Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer.J Clin Invest 91: 53–60, 1993

    Google Scholar 

  55. Mustonen T, Alitalo K: Endothelial receptor tyrosine kinases involved in angiogenesis.J Cell Biol 1251: 895–898, 1995

    Google Scholar 

  56. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease.Nat Med 1: 27–31, 1995

    Google Scholar 

  57. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VECF) and its receptors.FASEB J 13: 9–22, 1999

    Google Scholar 

  58. Levitzki A: Signal-transduction therapy.A novel approach to disease management.Eur J Biochem 226: 1–13, 1994

    Google Scholar 

  59. Gazit A, Yaish P, Gilon C, Levitzki A: Tyrphostins I; synthesis and biological activity of protein tyrosine kinase inhibitors.J Med Chem 32: 2344–2352, 1989

    Google Scholar 

  60. Gazit A, Osherov N, Posner I, Yaish P, Poradosu E, Gilon C, Levitzki A: Tyrphostins II: hetercyclic and-substituted benzylide-nemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases.J Med Chem 34: 1897–1907, 1991

    Google Scholar 

  61. Shiraishi T, Owada MK, Tatsuka M, Fuse Y, Kiyoshi W, Kakunaga T: A tyrosine-specific protein kinase inhibitor, alpha-cyano-3-ethoxy-4-hydroxy-5-phenylthiomethylcinnamide, blocks the phosphorylation of tyrosine kinase in intact cells.Jpn J Cancer Res 81: 645–652, 1990

    Google Scholar 

  62. Levitzki A, Gazit A: Tyrosine kinase inhibition: An approach to drug development.Science 267: 1782–1788, 1995

    Google Scholar 

  63. Klohs WD, Fry DW, Kraker AJ: Inhibitors of tyrosine kinase.Curr Opin Oncol 9: 562–568, 1997

    Google Scholar 

  64. Kelloff GJ, Fay JR, Steele VE, Lubet RA, Boone CW, Crowell JA, Sigman CC: Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives.Canc Epidem Biomark Prev 5: 657–666, 1996

    Google Scholar 

  65. Stavric V: Quercetin in our diet: from potent mutagen to probable anticarcinogen.Clin Biochem 27: 245–248, 1994

    Google Scholar 

  66. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y: Genistein, a specific inhibitor of tyrosine-specific protein kinases.J Biol Chem 262: 5592–5595, 1987

    Google Scholar 

  67. Kim H, Peterson TG, Barnes S: Mechanisms of activation of the soy isoflavone genistein: emerging role for its effects via transforming growth factor beta signaling pathways.Am J Clin Nutr 68: 1418S–1425S, 1998

    Google Scholar 

  68. Peterson TG, Coward L, Kirk M, Falany CN, Barnes S: The role of metabolisn in mammary epithelial cell growth inhibition by the isoflavones genistein and biochanin A.Carcinogenesis 17: 1861–1869, 1996

    Google Scholar 

  69. Xuan Y, Hacker MP, Tritton TR, Bhushan A: Modulation of methotrexate resistance by genistein in murine leukemia L1210 cells.Oncol Rep 5: 419–421, 1998

    Google Scholar 

  70. Uckun FM, Narla RK, Jun X, Zeren T, Venkatachalam T, Waddick KG, Rostostev A, Myers DE: Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells.Clin Cancer Res 4: 901–912, 1998

    Google Scholar 

  71. Lei W, Mayotte JE, Levitt ML: EGF dependent and independent programmed cell death pathways in NCI-H596 non-small cell lung cancer cells.Biochem Biophys Res Communications 245: 939–945, 1998

    Google Scholar 

  72. Uckun FM, Narla RK, Zeren T, Yanishevski Y, Myers DE, Waurzyniak B, Ek O, Schneider E, Messinger Y, Chelstrom LM, Gunther R, Evens W: In vivo toxicity, pharmacokinetics and anticancer activity of genistein linked to recombinant human epidermal growth factor.Clin Cancer Res 4: 1125–1134, 1998

    Google Scholar 

  73. Theodorescu D, Laderoute KR, Calaoagan JM, Guilding KM: Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression.Int J Cancer 78: 775–782, 1998

    Google Scholar 

  74. Yan C, Han R: Suppression of adhesion-induced protein tyrosine phosphorylation decreases invasive and metastatic potentials of B16-BL6 melanoma cells by protein tyrosine kinase inhibitor genistein.Invasion Metastasis 17: 189–198, 1997

    Google Scholar 

  75. Wei H, Bowen R, Zhang X, Lebwohl M: Isoflavone genistein inhibits the initiation and promotion of two-stage skin carcinogenesis in mice.Carcinogenesis 19: 1509–1514, 1998

    Google Scholar 

  76. Ahmad N, Gali H, Javed S, Agarwal R: Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression.Biochem Biophys Res Commun 247: 294–301, 1998

    Google Scholar 

  77. Cushman M, Zhu H, Geahlen RL, Kraker AJ: Synthesis and biochemical evaluation of a series of aminoflavones as potential inhibitors of protein-tyrosine kinases p56lck, EGFr and p60v-src.J Med Chem 37: 3353–3365, 1994

    Google Scholar 

  78. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW, Bridges AJ: A specific inhibitor of the epidermal growth factor receptor tyrosine kinase.Science 265: 1093–1095, 1994

    Google Scholar 

  79. Osherov N, Levitzki A: Epidefmal-gtowth-factor-dependent activation of the src-family kinases.Eur J Biochem 225: 1047–1053, 1994

    Google Scholar 

  80. Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, McNamara DJ, Nelson JM, Sherwood V, Smaill JB, Trumpp-Kallmeyer S, Dobrusin EM: Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.Proc Natl Acad Sci USA 95: 12022–12027, 1998

    Google Scholar 

  81. Woodburn JR, Baarker AJ, Gibson KH, Ashton SE, Wakeling AE, Curry BJ, Scarlett L, Henthorn LR: ZD1839, an epidennal growth factor tyrosine kinase inhibitor selected for clinical development.Proc AnnuMeet AmAssoc Cancer Res 38: A4251, 1997

    Google Scholar 

  82. Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA, Vaidya MP, Iwata K: Therapy of human carcinomas in athymic mice by inhibition of EGF receptor mediated signal transduction with CP-358774: Dynamics of receptor inhibition and antitumor effects.Proc Annu Meet Am Assoc Cancer Res 38: A4249, 1997

    Google Scholar 

  83. Iwata K, Miller PE, Barbacci EG, Arnold L, Doty J, DiOrio CI, Pustilnik LR, Reynolds M, Thelemann A, Sloan D, Moyer JD: CP-358,774: A selective EGFR kinase inhibitor with potent antiproliferative activity against HN5 head and neck tumor cells.Proc Annu Meet Am Assoc Cancer Res 38: A4248, 1997

    Google Scholar 

  84. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, Neveau M, Pollack VA, Pustilnik LR, Reynolds MM, Sloan D, Theleman A, Miller P: Induction of apoptosis and cell cycle arrest by CP-358,774, and inhibitor of epidermal growth factor receptor tyrosine kinase.Cancer Res 57: 4838–4848, 1997

    Google Scholar 

  85. Hartman RR, Rimoldi D, Lejeune FJ, Carrel S: Cell differentiation and cell-cycle alterations by tyrosine kinase inhibitors in human melanoma cells.Melanoma Res 7: S27–S33, 1997

    Google Scholar 

  86. Modjtahedi H, Affleck K, Stubberfield C, Dean C: EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5.Int J Oncol 13: 335–342, 1998

    Google Scholar 

  87. Kunkel MW, Hook KE, Howard CT, Przbranowski S, Roberts BJ, Elliott WL, Leopold WR: Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice.Invest New Drugs 13: 295–302, 1996

    Google Scholar 

  88. Jones HE, Dutkowski CM, Barrow D, Harper ME, Wakeling AE, Nicholson RI: New EGF-R selective tyrosine kinase inhibitor reveals variable grwoth responses in prostate carcinoma cell lines PC-3 and DU-145.Int J Cancer 71: 1010–1018, 1997

    Google Scholar 

  89. Woodburn JR, Barker AJ, Wakeling AE, Valcaccia BE, Cartlidge SA, Davies DH: 6-Amino-4-(3-methylphenylamino)-quinazoline: an EGF receptor tyrosine kinase inhibitor with activity in a range of human tumor xenografts.Proc Annu Meet Am Assoc Cancer Res 37: A2465, 1996

    Google Scholar 

  90. Baguley BC, Marshall ES, Holdaway KM, Rewcastle GW, Denny WA: Inhibition of growth of primary human tumour cell cultures by a 4-anilinoquinazoline inhibitor of the epidermal growth factor receptor family of tyrosine kinases.Eur J Cancer 34: 1086–1090, 1998

    Google Scholar 

  91. Uehara Y, Murakami Y, Suzukake-Tsuchiya KK, Moriya Y, Sano H, Shibata K, Omura S: Effects of herbimycin derivatives on src oncogene function in relation to antitumor activity.J Antibiot 41: 831–834, 1988

    Google Scholar 

  92. Billis WM, White BA: Effects or the protein tyrosine kinase inhibitor, herbimycin A, on prolactin gene expression in GH3 and 235-1 pituitary tnmor cells.Biochem Biophys Acta 1358: 31–38, 1997

    Google Scholar 

  93. Murakami Y, Fukazawa H, Mizuno S, Uehara Y: Effect of herbimycin A on tyrosine kinase receptors and platelet derived growth factor (PDGF)-induced signal transduction.Biol Pharm Bull 21: 1030–1035, 1998

    Google Scholar 

  94. Mimnaugh EG, Chavany C, Neckers L: Polyubiquitination and proteosomaldegradation of the p185c-erbB2 receptor protein-tyrosine kinase induced by geldanamycin.J Biol Chem 271: 22796–22801, 1996

    Google Scholar 

  95. Hartmann F, Horak EM, Cho C, Lupu R, Bolen JB, Stetler-Stevenson MA, Pfreundschuh M, Waldmann TA, Horak ID: Effects of the tyrosine-kinase inhibitor geldanamyn on ligand-induces Her-2/neu activation, receptor expression and proliferation of Her-2-positive malignant clees.Int J Cancer 70: 221–229, 1997

    Google Scholar 

  96. Brunton VG, Lear MJ, McKeown P, Robins DJ, Workman P: Synthesis and antiproliferative activity of tyrphostins containing quinolone moieties.Anticancer Drug Res 11: 463–483, 1996

    Google Scholar 

  97. Orfi L, Kokosi J, Szasz G, Kovesdi L, Mak M, Teplan I, Keri G: Heterocondensed quinazolones: synthesis and protein-tyrosine kinase inhibitory activity of 3,4-dihydro-1H,6H-[1,4]oxazino-[3,4-b]quinazolin-6-one derivatives.Bioorg Med Chem 4: 547–551, 1996

    Google Scholar 

  98. Rewcastle GW, Palmer BD, Thompson AM, Bridges AJ, Cody DR, Zhou H, Fry DW, McMichael A, Denny WA: Tyrosine kinase inhibitors: 10.Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyfosine kinase function of the epidermal growth factor receptor.J Med Chem 39: 1823–1835, 1996

    Google Scholar 

  99. Rewcastle GW, Murray DK, Elliott WL, Fry DW, Howard CT, Nelson JM, Roberts BJ, Vincent PW, Showalter HD, Winters R T, Denny WA: Tyrosine kinase inhibitors: 14.Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidin (PD158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.J Med Chem 41: 742–751, 1998

    Google Scholar 

  100. Brown C, McNeil L, Mendelsohn J, Fry DW: An epidermal growth factor (EGF) receptor specific tyrosine kinase inhibitor blocks receptor activation and inhibits growth in squamous carcinoma of the cervix.Proc Annu Meet Am Assoc Cancer Res 38: A3151, 1997

    Google Scholar 

  101. Slintak V, Keller PR, Rewcastle GW, Denny WA, Fry DW: PD158780 is a potent inhibitor of heregulin-dependent tyrosine pbosphorylation of erbB2, erbB3 and erbB4.Proc Annu Meet An Assoc Cancer Res 38: A3145, 1997

    Google Scholar 

  102. Elliott WL, Fry DW, Vincent PW, Roberts BJ, Howard CT, Slintak V, Nelson JM, Hook KE, Showalter HD, Winters TR, Denny WA, Thompson AM: In vitro and in vivo activity of 4-anilinopyridopyrimidine EGF family specific tyrosine kinase inhibitors.Proc Annu Meet Ant Assoc Cancer Res 38: A3144, 1997

    Google Scholar 

  103. Klutchko SRR, Hamby JM, Boschelli DH, Wu Z, Kraker AJ, Amar AM, Hartl BG, Shen C, Klohs WD, Steinkampf RW, Driscoll DL, Nelson JM, Elliott WL, Roberts BJ, Stoner CL, Vincent PW, Dykes DJ, Panek RL, Lu GH, Major TC, Dahring TK, Hallak H, Bradford LA, Showalter HD, Doherty AM: 2-Substituted aminopyrido[2,3-d]pyrimidin7(8H)-ones.Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.J Med Chem 41: 3276–3292, 1998

    Google Scholar 

  104. Lyndon NB, Mett H, Mueller M, Beckker M, Cozens RM, Stover D, Daniels D, Taxler P, Buchdunger E: A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo.Int J Cancer 76: 154–163, 1998

    Google Scholar 

  105. Traxler PM, Furet P, Mett H, Buchdunger E, Meyer T, Lydon N: 4-(Phenylamino)pyrrolopyrimidines: Potent and selective ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.J Med Chem 39: 2285–2292, 1996

    Google Scholar 

  106. Umezawa H, Imoto M, Sawa T, Isshiki K, Matsuda N, Uchida T, Iinuma, H, Hamada M, Takeuchi T: Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH435-hF3.J Antibiot 39: 170–173, 1986

    Google Scholar 

  107. Levitzki A: Tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction.PASEB J 6: 3275–3283, 1992

    Google Scholar 

  108. Gazit A, Osherov N, Posner L, Bar-Sinai A, Gilon C, Levitski A: Tyrphostins: Structure-activity relationship studies of alpha-substituted benzylidenemalononitrile 5-Saryltyrphostins.J Med Chem 36: 3556–3564, 1993

    Google Scholar 

  109. Simizu S, Umezawa K, Takada M, Arber N, Imoto M: Induction of hydrogen peroxide production and Bax expression by caspase-3(-like) proteases in tyrosine kinase inhibitorinduced apoptosis in human small cell lung carcinoma cells.Exp Cell Res 238: 197–203, 1998

    Google Scholar 

  110. Osherov N, Gazit A, Gilon C, Levitski A: Selective inhibition of the epidermal growth factor and HER-2/neu receptors by tyrphostins.J Biol Chem 268: 11134-11142, 2993

  111. Novogrodsky A, Weisspapir M, Patya M, Meshorer A, Vanichkin A: Tyrphostin 4-nitrobenzylidene malononitrile reduces chemotherapy toxicity without impairing efficacy.Cancer Res 58: 2397–2403, 1998

    Google Scholar 

  112. Liang BC, Ullyatt E: Chemosensitization of glioblastoma cells to bis-dichloroethyl-nirosourea with tyrphostin AG17.Clin Cancer Res 4: 773–781, 1998

    Google Scholar 

  113. Bartlett JM, Brunton V, Morrison V, Cooke TG: EGF and c-erbB-2 selective tyrosine kinase inhibitors block EGF mediated proliferation and reduce EGF, c-erbB2 and MAP kinase activation in gastric cancer cell lines.Br J Cancer 73: 7, 1996

    Google Scholar 

  114. Tsai CM, Levitski A, Wu LH, Chang KT, Cheng CC, Gazit A, Perng RP: Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells.Cancer Res 56: 1068–1074, 1996

    Google Scholar 

  115. Zhang L, Hung MC: Sensitization of HER-2/neuoverexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase: inhibitor emodin.Oncogene 12: 571–576, 1996

    Google Scholar 

  116. Zhang L, Lau YK, Xi L, Hong RL, Kim DS, Chen CF, Hortobagyi GN, Chang C, Hung MC: Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties.Oncogene 16: 2855–2863, 1998

    Google Scholar 

  117. Han Y, Caday CG, Umezawa K, Nanda A: Preferential inhibition of glioblastoma cells with wild-type epidermal growth factor receptors by a novel tyrosine kinase inhibitor ethyl-2,5-dihydroxycinnamate.Oncol Res 9: 581–587, 1997

    Google Scholar 

  118. Kobari M, Kullenberg B, Bjorkman A, Matsuno S, Ihse I, Axelson J: The inhibitory effect of an EGF receptor-specific tyrosine kinase inhibitor on pancreatic cancer cell lines was more potent than inhibitory antibodies against the receptors for EGF and IGF I.Int J Pancreatol 24: 85–95, 1998

    Google Scholar 

  119. Westermark B, Heldin CH: Platelet-derived growth factor: Structure, function and implications in normal and malignant cell growth.Acta Oncol 32: 101–105, 1993

    Google Scholar 

  120. Klohs W, Steinkampf R, Driscoll D, Klutchko S, Hamby J, Lu G, Vincent P, Roberts B, Elliott W: Characterization of PDGF tyrosine kinase inhibitors in in vitro and in vivo tumors.Proc Annu Meet Am Assoc Cancer Res 38: A4244, 1997

    Google Scholar 

  121. Buchdunger E, Zimmermann J, Mett H, Meyer T, Mueller M, Regenass U, Lyndon NB: Selective inhibition of the platelet derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.Proc Natl Acad Sci USA 92: 2558–2562, 1995

    Google Scholar 

  122. Yoneda J, Fidler IJ, Kumar R, Bucana CD, Killion JJ, Radinskky R: Inhibitory effect of platelet derived growth factor receptor (PDGF-R) tyrosine kinase (TK) inhibitor, CGP 53716, on tumor stroma formation, angiogenesis, and orthotopic growth of human lung carcinoma cells in nude mice.Proc Annu Meet Am Assoc Cancer Res 38: A4245, 1997

    Google Scholar 

  123. Kovalenko M, Gazit A, Bohmer A, Rorsman C, Ronnstrand L, Heldin CH, Waltenberger J, Bohmer FD, Levitzki A: Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation.Cancer Res 34: 6106–6114, 1994

    Google Scholar 

  124. Showalter HD, Sercel AD, Leja BM, Wolfnagel CD, Ambroso LA, Elliott WL, Fry DW, Kraker AJ, Howard CT, Lu GH, Moore CW, Nelson JM, Roberts BJ, Vincent PW, Denny WA, Thompson AM: Tyrosine kinase inhibitors.6.Structure-activity relationships among N-and 3-substituted 2,2′-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur cogeners.J Med Chem 40: 413–426, 1997

    Google Scholar 

  125. Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK, Hubbard SR, Schlessinger J: Structure of the tyrosine kinase domain of the fibroblast factor receptor in complex with inhibitors.Science 276: 955–960, 1997

    Google Scholar 

  126. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth KP, Shawver LK: Flk-1 as a target for tumor growth inhibition.Cancer Res 56: 3540–3545, 1996

    Google Scholar 

  127. Fong TAT, McMahon G, Kim Y, Sun L, Tang C, Chen J, Sutton B, Schreck R, Smolich B, Jacobs J, Shawver LK: Small molecule inhibitors of Flk-1 suppress subcutaneous growth of muhiple tumor types, inhibit tumor angiogenesis, and provide attenuation of metastasis.Proc Annu Meet Am Assoc Cancer Res 38: A1789, 1997

    Google Scholar 

  128. Wood J, Mett H, Stover D, Buchdunger E, Siemeister G, Martiny-Baron G, Marme D, Fabbro D: CGP41251, an inhibitor of VEGF receptor tyrosine kinases.Proc Annu Meet Am Assoc Cancer Res 38: A1787, 1997

    Google Scholar 

  129. Kraker AJ, Moore CW, Amar AM, Shen CS, Nelson J, Slintak V, Fry DW, Lu G, Panek R, Klutchko S, Hamby J: Cytotoxicity and phosphotyrosine effects of c-src kinase inhibition by substituted pyridopyrimidine tyrosine kinase inhibitors in human colon carcinoma cell lines.Proc Annu Meet Am Assoc Cancer Res 38: A4247, 1997

    Google Scholar 

  130. Krystal GW, DeBerry CS, Linnekin D, Litz J: Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1.Cancer Res 58: 4660–4666, 1998

    Google Scholar 

  131. Krystal GW, Carlson P, Litz J: Induction of apoptosis and inhibition of small cell lung cancer growth by the quinoxaline tyrphostins.Cancer Res 57: 2203–2208, 1997

    Google Scholar 

  132. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok BA, Connelly PA: Discovery of a novel, potent, and src-family selective tyrosine kinase inhibitor.J Biol Chem 271: 495–701, 1996

    Google Scholar 

  133. Dionne CA, Camoratto AM, Jani JP, Emerson E, Neff N, Vaught JL, Murakata C, Djakiew D, Lamb J, Bova S, George D, Isaacs JT: Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).Clin Cancer Res 4: 1887–1898, 1998

    Google Scholar 

  134. Dionne CA, Camoratto AM, Jani JP, Vaught J, Murakata C, Djakiew D, Bova S, George D, Isaacs JT: Inhibition of prostate tumor growth by the trk-selective tyrosine kinase inhibitor, CEP-751 (KT-6587).Proc Annu Meet Am Assoc Cancer Res 38: A4254, 1997

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chaim Sheba Medical Center, affiliated with the Tel Aviv University Sackler School of Medicine, Institute of Oncology, Tel Hashomer, Israel

    Mark L. Levitt

  2. Graduate School of Public Health, Department of Environmental and Occupational Health, Pittsburgh, PA, USA

    Patrick P. Koty

Authors
  1. Mark L. Levitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrick P. Koty
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Levitt, M.L., Koty, P.P. Tyrosine Kinase Inhibitors in Preclinical Development. Invest New Drugs 17, 213–226 (1999). https://doi.org/10.1023/A:1006372102543

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006372102543

Search

Navigation